These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7736528)

  • 1. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma.
    Wagner U; Reinsberg J; Schmidt S; Mallmann P; Schmolling J; Schultes B; Richter H; Biersack HJ; Krebs D
    Cell Biophys; 1994; 24-25():237-42. PubMed ID: 7736528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.
    Wagner UA; Oehr PF; Reinsberg J; Schmidt SC; Schlebusch HW; Schultes B; Werner A; Prietl G; Krebs D
    Biotechnol Ther; 1992; 3(1-2):81-9. PubMed ID: 1305894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic cascades after injection of the monoclonal antibody OC125. A study in a mouse model.
    Schultes BC; Reinsberg J; Wagner U; Schlebusch H; Richter H; Krebs D; Biersack HJ
    Cell Biophys; 1994; 24-25():259-66. PubMed ID: 7736531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
    Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
    Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
    Wagner U; Reinsberg J; Krebs D
    Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immunization with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotypic network.
    Schultes BC; Reinsberg J; Schlebusch H; Oehr P; Biersack HJ; Krebs D; Wagner U
    Eur J Clin Chem Clin Biochem; 1993 Jul; 31(7):427-32. PubMed ID: 8399782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?
    Reinsberg J; Krebs D
    Hybridoma; 1997 Feb; 16(1):59-63. PubMed ID: 9085130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and expression of a single chain antibody mimicing human ovarian cancer antigen CA125.
    Li AD; Li Z; Wang YH; Zhang YM; Ma J
    Cell Mol Immunol; 2006 Feb; 3(1):59-62. PubMed ID: 16549051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
    Ma J; Zhou L; Wang D
    Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
    Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
    Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
    Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
    Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres.
    Ma J; Samuel J; Kwon GS; Noujaim AA; Madiyalakan R
    Cancer Immunol Immunother; 1998 Sep; 47(1):13-20. PubMed ID: 9755874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer.
    Schlebusch H; Wagner U; Grünn U; Schultes B
    Hybridoma; 1995 Apr; 14(2):167-74. PubMed ID: 7590775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotypic cascades after MAb OC125 application.
    Reinsberg J
    Hybridoma; 1993 Oct; 12(5):577-82. PubMed ID: 8300133
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).
    Schultes BC; Baum RP; Niesen A; Noujaim AA; Madiyalakan R
    Cancer Immunol Immunother; 1998 Jun; 46(4):201-12. PubMed ID: 9671143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
    Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
    Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune reactions and survival of patients with ovarian carcinomas after administration of 131I-F(Ab)2 fragments of the OC 125 monoclonal antibody].
    Schmolling J; Wagner U; Reinsberg J; Biersack HJ; Krebs D
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):200-3. PubMed ID: 7789708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.
    Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ
    Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.